Synlogic, Inc. (NASDAQ:SYBX) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 08:00 am ET


Synlogic, Inc. (NASDAQ:SYBX) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning. Welcome to Synlogic's Second Quarter 2020 Conference Call. [Operator Instructions] Please be advised that this call is being recorded. I would now like to turn the call over to Daniel Rosan, Head of Corporate Finance and Investor Relations. Please proceed.

Daniel Rosan

Thank you, operator. Good morning, and thanks for joining us on today's conference call. This morning, we issued a press release, which outlines our second quarter 2020 financial results and several other topics that we plan to discuss today. The release is available on the Investors section of our website at

Joining me this morning are Aoife Brennan, President and Chief Executive Officer; Gregg Beloff, Interim Chief Financial Officer; and Richard Riese, Chief Medical Officer. Also joining us today for questions is Tony Awad, our newly appointed Chief Operating Officer. Congratulations, Tony. During the call, Aoife will provide a brief outline of second quarter highlights and recent projects, Gregg will summarize our financial results for the quarter, and Richard will provide an overview and update on our enteric hyperoxaluria program. Following our prepared remarks, we'll open the call for your questions.

As we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date hereof and are subject to numerous factors, assumptions, risks and uncertainties, which change over time. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including those described under the heading forward-looking statements in Synlogic's press release from earlier today or under the heading Risk Factors in Synlogic's most recent Form 10-K or in later filings with the SEC. Synlogic cautions you not to place undue reliance on any forward-looking statements.

And now, I'd like to turn the call over to Aoife.

Aoife Brennan

Thanks Dan. Good morning, everyone, and thank you for joining us on our call to discuss our second quarter 2020 financial results, recent progress and upcoming milestones.

As I recently recalled during our R&D Day, it's about four years since I first heard about Synlogic and the concept of using synthetic biology to engineer bacterial cells to create a new class of therapeutics. The idea that we could treat diseases in a fundamentally new way captured my attention, both in terms of the challenge of working out how but more importantly, the potential I thought offer hope to patients with devastating diseases. I'm pleased to report that the underlying concept of our company excites me just as much today as it did on my first day at Synlogic. We have made great progress in bringing the promise of synthetic biology to drug development and are building the premier synthetic biology platform to engineer bacterial synthetic biotic medicines that benefit patients in new ways.

Our momentum is accelerating. And I know we have the team, technology and portfolio to succeed. This, coupled with a strong cash position, ensures that we have the resources to